Laser enucleation of the prostate: Overview of our results after the first 18 months of acquisition by Kharbach, Y et al.
African Journal of Urology (2017) 23, 245–248
African  Journal  of  Urology
Official journal of the Pan African Urological Surgeon’s Association
web page of the journal
www.ees.elsevier.com/afju
www.sciencedirect.com
BPH and Prostate Diseases
Original article
Laser  enucleation  of  the  prostate:  Overview  of
our  results  after  the  first  18  months  of  acquisition
Y.  Kharbach a,b,∗,  S.  Tenkorang b,  T.  Gateau a,  M.H.  Farih b,  F.  Junès a
a Urology  Department,  Robert  Boulin  Hospital,  Libourne  33500,  France
b Urology  Department,  Hassan  II  Teaching  Hospital,  Fez  30000,  Morocco
Received 12 June 2016; received in revised form 18 February 2017; accepted 3 March 2017







Introduction:  New techniques using laser are now available as an alternative to conventional techniques in
the treatment of benign prostatic hyperplasia (BPH). Holmium laser enucleation of the prostate (HoLEP)
reproduces via endoscopy have shown results similar to that of open prostatectomy.
Objective:  To give an overview of the use of HoLEP in Robert Boulin hospital (Libourne, FRANCE) and
to study its feasibility even in a center that has no prior experience in this technique.
Patients and  methods:  This is a retrospective descriptive study from November 2013 to April 2015 of all
patients who underwent HoLEP by two urologists with no prior experience of this technique.
Results: In total, 138 patients underwent HoLEP with mean age of 74.59 ±  9.96 (56–90) years and a median
of 75 years. The mean preoperative prostate volume was 59.61 ±  18.86 (30–180) ml. The average operative
time was 103.03 ±  31.07 (50–150) min. The resected weight was 55.75 ±  19.04 g with a delivered energy of
186.3 ±  52.4 kJ. The duration for keeping urethral catheters and hospitalization were 1.1 (1–2) and 1.4 (1–4)
days. Eighteen patients experienced at least one perioperative complication of which four were converted
to TURP and two required bladder clot evacuation.
Twenty patients had postoperative complications including of which eleven required urethral catheter
reinsertion. There was a significant improvement in IPSS and Qmax at the 3rd month postoperative review.
Conclusion:  HoLEP is a promising technique that has proven to be safe and reproducible. Through the
analysis of our results we have shown the presence of a learning curve and predictive values of sometients
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Table  1  Demographics and preoperative.
Age 74.59 ± 9.96
Comorbidities
HBP 30
Ischemic or valvular heart disease 28
Diabetes 36
Chronic renal failure 8
Bronchopulmonary pathology 12
Rheumatic disease 16
Prostate volume (ml) 59.61 ± 18.86
Qmax 9.50 ± 5.88
IPSS 22.64 ± 6.42
Surgical indication
Recurrent acute urinary retention 40 (28.9%)
Medical treatment failure 56 (40.5%)
Bladder calculi 15 (10.8%)
Recurrent urinary tract infections 10 (7.2%)
Renal failure 5 (3.6%)
Patient request 12 (8.7%)
Table  2  Perioperative data.
Operating time (minutes) 103.03 ± 31.07
Energy used (kJ) 186.3 ± 52.4
Resected prostate volume (g) 55.75 ± 19.04
Perioperative Complications
Perforation of the capsule 12
Conversion to RTUP 4
Bladder mucosa injury 6
Transfusion 2
Table  3  Post operative data.
Duration of post operative urethral catheter (days) 1.1
Duration of hospitalization (days) 1.4





Table  4  Evolution of IPSS and Qmax.












enign prostatic hyperplasia (BPH) is a real health problem for men
s they gradually advance in age [1]. At age 80, approximately 50%
f men have low urinary tract disorders that alter their quality of life
2].
oday new techniques using laser such as (HoLEP) are available as
n alternative to conventional methods of treatment of BPH and can
eproduce results via endoscopie identical to open prostatectomy.
his new technique is the most studied of all the therapeutic options
or BPH [3].
bjective
o give an overview of the use of HoLep in Robert Boulin hospital
Libourne) and to study its feasibility in a center that has no prior
xperience in this technique.
atients  and  methods
his is a descriptive and analytical retrospective study of all patients
ho underwent holmium laser enucleation of the prostate (HoLEP)
y two urologists with no previous experience in this technique from
ovember 2013 to April 2015.
ll patients underwent a careful history, a complete physical exam-
nation including DRE with an assessment of symptoms using the
PSS score, a urine flow test and an assessment of post void residual
rine.
e used a holmium: YAG laser with 100 W 550   fiber in a 28ch
esectoscope. The enucleated adenoma was removed from the blad-
er through a rigid nephroscope allowing morcellation.
lavien-Dindo classification was used to determine complications.
esults
emographic  and  preoperative  data
n total, 138 patients underwent HoLEP with mean age of
4.59 ±  9.96 (56–90) years and a median of 75 years. Diabetes
nd heart disease were the most frequent comorbidities. The mean
reoperative prostate volume was 59.61 ±  18.86 (30–180) ml. The
aximum flow rate (Qmax) was 9.50 ml/s. The most common indi-
ation for surgery was medical treatment failure (Table 1).
ntraoperative  data
he average operative time was 103.03 ±  31.07 (50–150) min. The
esected weight was 55.75 ±  19.04 g with a delivered energy of
86.3 ±  52.4 kJ. The duration for urethral catheterization and hos-
italization were 1.1 (1–2) and 1.4 (1–4) days. Eighteen patients
xperienced at least one perioperative complication if which four
ere converted to TURP (Table 2).ostoperative  data
wenty patients had postoperative complications including eleven




IPSS 22.64 4.65 0.01
Qmax 9.5 24.78 0.005
nly 3 patients kept an indwelling catheter for 48 additional hours
fter surgery. Clinical review at the 3rd month showed significant
mprovement in IPSS and Qmax (Table 4).
iscussion
rans urethral resection of the prostate and open prostatectomy have
een considered the treatment of choice for symptomatic benign
rostate hyperplasia for many decades [4]. Despite the good treat-
ent results, there is a significant risk of complications for both
echniques, thus explaining the unceasing efforts in researching
lternative therapeutic options such as laser therapy methods [5].
t is clear that Holmium laser treatments can be considered very
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(it can be used for the treatment of stones, for example), its reusable
fiber, its low rate of complications and the short length of hospital-
ization [3].
HoLEP has been a subject of several comparative studies after its
first description by Gilling et al. [6] these studies have shown sat-
isfactory results which is significantly better than other techniques
with less morbidity in certain cases [7]. Though studies on open
prostatectomy have shown better operating time and prostate vol-
ume removed, HoLEP causes lesser time for post operative urethral
catheterization, short period of hospitalization and lesser bleeding
complications [8].
We report our experience with this technique in our department as
the acquisition of this equipment required a significant investment.
HoLEP is the only endoscopic technique till date, which has demon-
strated its superiority over trans urethral prostatic resection [9].
However, it requires longer learning curve; an average of 15 inter-
ventions would be required for the acquisition of confidence by
the surgeon [5,10] who can produce similar results as compared to
experts in this technique after 50 interventions [5,11,12].
The operating time is significantly longer as compared to TURP, it
is mainly influenced and directly related to the size of the prostate
[13]. Several studies have suggested better efficiency of HoLEP with
larger prostates [13–15], but by comparing the rate of tissue retrieval
rates (grams per minute) we noticed that there was no significant
difference 0.52 g/min vs. 0.57 g/min) [9].
The mean duration for postoperative hospitalization and urethral
catheterization are respectively 1.1 and 1.4d. We find the same
periods in international publications [3,12]. This demonstrates the
superiority of the HoLEP over open surgery in postoperative mor-
bidity [16].
Potential intraoperative complications are capsular perforation and
lesions of the bladder mucosa [9,17]. Studies have shown that
HoLEP has a lesser rate of post operative complications to that of
TURP [7], no TURP syndrome has been described even with greater
prostatic volumes [7,9].
In our study, systematic follow up conducted at 3 months after
surgery showed a significant improvement in IPSS and Qmax. A meta
analysis that compared the functional outcomes of minimally inva-
sive TURP techniques showed that HoLEP was the only technique
that has proven superior in improving IPSS [9].
Elzayat et al. [18] investigated the usefulness of this technique in
patients on anticoagulants. This study found HoLEP to be a safe
alternative as the laser coagulates and enucleates at the same time.
Currently there is no limitation on prostate volume in using HoLEP;
it can be used on any prostate gland size [9,19,20], and therefore
this procedure may possibly replace open prostatectomy. Published
cases of operated patients with 800 g of adenomas could confirm
this hypothesis [7,21].Conclusion
HoLEP is a promising technique that has proven to be safe and
reproducible. We have demonstrated through the analysis of our247
esults its feasibility even in a center that has no prior experience
n this technique as these results are significantly acceptable. It is a
echnique that is rapidly gaining ground and which is becoming the
old standard for the treatment of benign prostatic hyperplasia.
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